Wellcome Trust taps into demand for long-dated bonds
Your support helps us to tell the story
From reproductive rights to climate change to Big Tech, The Independent is on the ground when the story is developing. Whether it's investigating the financials of Elon Musk's pro-Trump PAC or producing our latest documentary, 'The A Word', which shines a light on the American women fighting for reproductive rights, we know how important it is to parse out the facts from the messaging.
At such a critical moment in US history, we need reporters on the ground. Your donation allows us to keep sending journalists to speak to both sides of the story.
The Independent is trusted by Americans across the entire political spectrum. And unlike many other quality news outlets, we choose not to lock Americans out of our reporting and analysis with paywalls. We believe quality journalism should be available to everyone, paid for by those who can afford it.
Your support makes all the difference.The Wellcome Trust, Britain's largest charitable foundation, is launching its first bond to raise money to invest in scientific research ranging from the human genome to bird flu and malaria.
The trust is following the lead of US organisations to become the first UK charity to sell a public bond, it said yesterday.
It hopes to raise £300m to £500m when it issues the 30-year bond next week. The move is intended to tap into unmet demand from pension funds for long-dated sterling bonds, as they seek to match liabilities with secure long-term investments.
The Wellcome Trust intends to plough the money raised into its investment portfolio which is used to fund research. The trust holds more than £12bn of investment assets and spends more than £450m a year on research and related activities. The organisation's funding of biomedical research is second only to that of the Bill & Melinda Gates foundation, set up by the Microsoft founder.
Set up in 1936, the Wellcome Trust funds 3,000 investigators and their research teams in 50 countries.
The organisation starts a roadshow today to gauge investor appetite in the bond issue and expects to launch it before the end of next week.
The rating agencies Moody's and Standard & Poor's have both rated the bond a triple A, the highest credit rating available. Bonds receive an AAA rating when they are judged to carry the smallest investment risk.
Danny Truell, the chief investment officer of the Wellcome Trust, said: "[The bond] gives us greater balance-sheet flexibility and should enhance our mission, which is promoting and fostering research with the aim of improving human health."
The trust has appointed Barclays, JP Morgan Cazenove and Morgan Stanley as joint bookrunners for the bond.
Its investment portfolio has seen average returns of 9 per cent a year over the past decade, according to Standard & Poor's. That means it should not find it hard to raise money from sterling bond investors cheaply which can then be reinvested in more exotic markets to achieve higher returns.
Join our commenting forum
Join thought-provoking conversations, follow other Independent readers and see their replies
Comments